MedPath

Effect of add on intravenous lignocaine on delirium and cognitive dysfunction after surgery in patients undergoing total hip replacement: a double blinded randomised controlled trial

Not Applicable
Conditions
Health Condition 1: M161- Unilateral primary osteoarthritisof hip
Registration Number
CTRI/2019/10/021816
Lead Sponsor
Eslavath Madhurima
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Closed to Recruitment of Participants
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

All patients above 18 years undergoing Total Hip Replacement.

Exclusion Criteria

Preexisting neurocognitive dysfunctions,

Refusal for the consent ,

Auditory or visual disability,

NuDESC score >2 pre-operatively,

MMSE score < 23 pre-operatively,

Subjects with known sensitivity to lignocaine,

On beta blocker therapy,

Hemodynamically unstable,

Subjects with deranged liver, renal functions

THR done under general anaesthesia.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath